Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
Date:10/26/2010

ove, the increase was approximately $44 million, or 22%. This increase is primarily driven by higher third party sales from India, with growth in third party sales in Australia and Japan also contributing.

For the current quarter, Specialty reported third party net sales of $141.1 million, a decrease of $6.8 million, or 4.6%, from the comparable prior year period of $147.9 million. The most significant contributor to Specialty Segment revenues continues to be the EpiPen® Auto-injector.  In the current quarter, Specialty realized increased sales of the EpiPen Auto-injector, mainly as a result of favorable pricing.

Intercompany net sales by Specialty totaled $13.7 million in the current quarter compared to $3.8 million in the same prior year period. The increase is due to the fact that, beginning in 2010, certain generic products previously sold to third parties by Specialty are now sold to Mylan subsidiaries in North America who, in turn, sell the products to third parties. Excluding the sale of such products from 2009 third party net revenues would have resulted in an increase in third party net revenues in the current quarter of approximately $8 million or 6%.

Gross profit for the three months ended September 30, 2010 was $580.1 million and gross margins were 42.8%. For the three months ended September 30, 2009, gross profit was $505.0 million, and gross margins were 39.9%. Gross profit for the current quarter is impacted by certain purchase accounting related items recorded during the three months ended September 30, 2010, of approximately $74.6 million, which consisted primarily of amortization related to purchased intangible assets.  Excluding such items, gross margins would have been approximately 48%. Prior year gross profit is also impacted by similar purchase accounting related items in the amount of $71.8 million. Excluding such items, gross margins in the prior year would have been approxima
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
3. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
4. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
5. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
6. Mylan Launches Generic Version of Wellbutrin XL® Tablets
7. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
8. Mylan Receives Approval for Generic Version of Prograf® Capsules
9. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
10. Mylan Announces Completion of Add-On Offering of Senior Notes
11. Mylan Announces Pricing of Add-On Offering of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... Wash. , Oct. 17, 2014  Talyst, a ... the 2014 LeadingAge Annual Meeting in Nashville, ... InSite System, the market leading solution for onsite, remote ... long term care facilities to safely and securely dispense ... time to first dose, helps ensure that the correct ...
(Date:10/17/2014)... , Oct. 17, 2014   InnFocus, Inc ., reported ... the United States for up to 3 years ... Summit in Chicago . The ... of the annual meeting of the American Academy of ... treated approximately 150 glaucoma patients in 6 countries by early ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... PHILADELPHIA and LONDON , June 28 ... portfolio of drugs, whilst the proportion of total sales from newer drugs ... Factbook complied by CMR International, a Thomson Reuters business. , ... The new edition of the R&D Factbook ...
... Fla. , June 26 Data ... that linagliptin achieved statistically significant and sustained reductions ... (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose ... dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral ...
Cached Medicine Technology:Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 2Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 2Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 4Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 5Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 6Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 7Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 8
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... The U.S. Government has initiated a major effort ... 2025. However, a workgroup of nearly 40 Alzheimer,s ... the U.S. Government,s National Plan to Address Alzheimer,s ... scale, and adequately funded in order to successfully ... the workgroup to enlarge and strengthen the Plan ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... a direct link between a human gene and the risk ... by Professor Marco Polo from the National Centre of Investigative ... mutation in the gene, known as Cdk4, were more likely ... appear in the latest issue of the Proceedings of the ...
... developed a non-invasive diagnostic tool that can study changes ... the brain activity.This technique is based uopn near-infrared spectroscopy ... other methods such as functional magnetic resonance imaging and ... UI professor of Physics, whenever the region of the ...
... from Angina may have some new treatment options involving ... common cardiovascular disorder affecting millions of people all over ... vessels too clogged to get oxygen-rich blood to the ... or for more serious cases, rerouting the blood vessels ...
... responsible for imitation may be behind ,the unique quality to ... of empathy have now found brain regions involved in learning ... regions that are involved in human imitation and specific ,brain ... others.// , The research, ...
... researchers, Americans will probably have to depend on current ... this year Second-generation vaccines are in the works but ... that's ready to go, approved by the FDA.// ... of the anthrax vaccine to resume shipping after four ...
... human fat cells may become key to the development ... According to Dr. Lucino Roseveltte, professor of medicine at ... there are molecules produced by the fat cells, the ... functions of different organs. Their research identifies one very ...
Cached Medicine News:Health News:Studying brain anatomy without surgery 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Fat Cell Protein Hits Type-2 Diabetes 2
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
... growth factor 1 (IGF-1) is a polypeptide of ... of a number of related insulin-like growth factors ... 50% sequence homology with proinsulin and has a ... peptide is growth hormone (GH) dependent to a ...
...
Medicine Products: